The FDA cleared the PreClara Ratio biomarker test, which Trinity Biotech is rolling out a service for in the US.
1 report, 1 independent
Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA cleared the PreClara Ratio biomarker test, which Trinity Biotech is rolling out a service for in the US.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Trinity Biotech announced that its Premier Hb9210™ analyser received FDA clearance and the company plans to accelerate growth across its diagnostics franchise in Europe.
- The FDA upheld the De Novo denial for DrugSorb-ATR, a product of CytoSorbents. Phillip Chan serves as the company's CEO.
- BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
Coverage
Newest first; wire copies grouped- GlobeNewswireTrinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disord